原发性肝癌γ刀配合增敏药和介入化疗疗效比较  

Clinical study of γ-knife combined with radiosensitizer and chemoembolization (TACE) for primary hepatocellular carcinoma

作　　者：康静波[1] 聂青[1] 张丽萍[1] 李启亮[1] 郑伟[1] 李建国[1] 齐文杰[1] 

机构地区：[1]海军总医院放疗科,北京100037

出　　处：《武警医学》2009年第10期894-897,共4页Medical Journal of the Chinese People's Armed Police Force

摘　　要：目的比较γ刀配合放射增敏药和介入化疗治疗原发性肝癌的临床效果。方法自2005年3月～2007年3月,收治81例原发性肝癌患者。46例给予体部γ刀配合放射增敏药治疗,35例给予γ刀配合放射增敏药及介入化疗栓塞治疗。结果治疗后3个月总的有效率为85.2%(69/81)。γ刀配合放射增敏组的1年、2年局部控制率分别为63.0%(29/46)、34.8%(16/46),1年、2年生存率分别为65.2%、37.0%。γ刀配合放射增敏及介入化疗栓塞组的1年、2年局部控制率分别为68.6%(24/35)、37.1%(13/35),1年、2年生存率分别为71.4%、42.9%。随访期内未见严重放射性并发症。结论对原发性肝癌采用γ刀配合放射增敏药和介入化疗栓塞进行治疗是较有效的局部治疗方式。Objective To investigate the clinical effect of γ- knife combined with radiosensitizer and chemoembolization on primary hepatocellular carcinoma. Methods Eighty - one patients with primary hepatoeellular carcinoma were treated from March 2005 to March 2007. Among them, 46 patients were treated with whole body γ- knife combined with radiosensitizer, 35 patients were treated with whole body γ- knife combined with radiosensitizer and chemoembolization. Results Three months after treatment, the overall response rate was 85.2% （69/81）. The local control rates at 1 and 2 years were 63.0% （29/46） and 34.8% （16/46） respectively, and the survival rate at 1 and 2 years were 65.2% and 37.0%, respectively in γ - knife combined with radiosensitizer group. The local control rates at 1 and 2 years were 68.6% （24/35） and 37.1% （13/35） respectively, and the survival rates at 1 and 2 years were 71.4% and 42.9% , respectively in γ- knife combined with radiosensitizer and chemoembolization group. No serious complications were found in the follow - up period. Conclusions γ- knife combined with radiosensitizer and chemoembolization is an effective treatment for the primary hepatoeellular carcinoma.

关 键 词：原发性肝癌 Γ刀 放射增敏药 介入化疗栓塞治疗 

分 类 号：R735.7[医药卫生—肿瘤]